Main Content

“2020health is an important and thoughtful contributor to the health debate”

Dr Sarah Wollaston MP, Chairman, Health Select Committee


Financial Times UK drug pricing plan could trigger ‘avalanche of problems’

2020health argues that valuing drug prices is “not a science capable of precision or consensus conclusions” but rather a “drug rationing system”.

It says it would be better to allow drug companies to continue fixing their own prices, while capping total profits or sales and lowering the price of their older drugs to offset higher prices for new ones.

Its report, co-written by a biotech industry consultant, cautions that “doctors, charities and the media may see value-based pricing not as something in which the government believes, but rather as a way of hiding behind jargon and intellectual dishonesty in order to justify what will increasingly feel like largely arbitrary rationing of expensive drugs”.


Read Full Article